Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

methylphenidate

Adjunctive therapy

Brands: RITALIN, CONCERTA, DAYTRANA, METADATE CD, QUILLIVANT XR

Published 2026-03-24 · Last reviewed 2026-03-31 · 5 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Adults (typical pattern): low morning dose with weekly titration based on benefit and tolerability; immediate-release products often need a noon dose, while extended-release products are typically once daily.·Half-life: Single-dose mean 3 h·LAI available: No

Class: Adjunctive therapy
Typical dose: Adults (typical pattern): low morning dose with weekly titration based on benefit and tolerability; immediate-release products often need a noon dose, while extended-release products are typically once daily.
Half-life: Single-dose mean 3 h
LAI available: No

Quick answers

What is methylphenidate?: Methylphenidate (brands include Ritalin and Concerta) is a Schedule II stimulant used as a first-line medication for attention-deficit/ hyperactivity disorder (ADHD) across age groups; it improves attention, organization, and impulse control when paired with behavioral and educational supports.
What is RITALIN?: RITALIN is a brand name for methylphenidate (other brands: CONCERTA, DAYTRANA, METADATE CD, QUILLIVANT XR).
What is RITALIN (methylphenidate) used for?: Label indications include: Attention-deficit/hyperactivity disorder (ADHD); narcolepsy (product-dependent).
What drug class is RITALIN (methylphenidate)?: CNS Stimulant.
What is the mechanism of action of RITALIN (methylphenidate)?: Central nervous system stimulant; inhibits dopamine and norepinephrine reuptake (DAT/NET).
What strengths does RITALIN (methylphenidate) come in?: Multiple oral formulations exist including immediate-release tablets, chewables, liquids, and extended-release capsules/tablets; delivery systems vary widely by brand.
What is the maximum recommended dose of RITALIN (methylphenidate)?: Maximum recommended dose depends on the specific product; respect the labeled maximum, and escalation beyond typical ranges often prompts reassessment of diagnosis, adherence, sleep, and comorbid anxiety.

General information

Methylphenidate is a Schedule II stimulant commonly used as a first-line medication for attention-deficit/hyperactivity disorder (ADHD). It can improve attention, working memory, and task follow-through when paired with behavioral supports and a clear functional target.

Formulation choice often drives outcomes as much as the molecule does. Immediate-release products emphasize flexibility and short duration; extended-release products emphasize once-daily dosing and smoother coverage with less midday “wear off.”

In populations with serious mental illness, stimulants are used selectively for comorbid ADHD or disabling inattention, but they can worsen anxiety, insomnia, irritability, mania, or psychosis in susceptible patients. Diagnosis confirmation, mood/psychosis stability, and cautious titration are common guardrails.

The methylphenidate compare view, the methylphenidate evidence feed, and the methylphenidate print page for patient counseling and monitoring.

U.S. approvals

Attention-deficit/hyperactivity disorder (ADHD)
Narcolepsy (product-dependent)

Formulations & strengths

Multiple oral formulations exist including immediate-release tablets, chewables, liquids, and extended-release capsules/tablets; delivery systems vary widely by brand.
Transdermal methylphenidate exists (brand Daytrana) for patients who cannot take oral products or need a non-oral delivery system.

Generic availability

Widely available generically in multiple immediate-release and extended-release forms.

The most common failures are (1) a mismatch between symptom target and formulation duration, (2) dose escalation that ignores sleep loss and anxiety, and (3) under-recognition of comorbid substance use or bipolar spectrum illness. Success depends on a structured titration plan with ongoing monitoring of appetite, sleep, blood pressure/heart rate, and psychiatric activation.

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Inhibits dopamine and norepinephrine reuptake transporters (DAT/NET), increasing catecholamine availability in cortical and striatal circuits relevant to attention and impulse control.

Clinical benefits are rapid relative to antidepressants (often same day) and are better measured via function (task completion, fewer mistakes, safer driving) than by subjective energy.

Because methylphenidate can increase arousal, it can worsen insomnia and anxiety when dosing is late or titration is too aggressive.

DAT/NET reuptake inhibition increases dopamine and norepinephrine signaling.
Limited direct serotonergic activity compared with many antidepressants.

Metabolism & pharmacokinetics

Primarily metabolized by carboxylesterase (CES1) to ritalinic acid; not a clinically meaningful CYP substrate.
Short intrinsic half-life (about 2–3 hours for immediate-release); longer clinical duration comes from extended-release delivery systems rather than slower clearance.
Food and formulation influence onset and peak effects; meal timing is often considered when patients report abrupt “kick in” or afternoon crashes.
Renal excretion is mainly as metabolites; dose adjustments are typically guided by clinical response rather than routine laboratory monitoring.

Dosing & administration

Adults (typical pattern): low morning dose with weekly titration based on benefit and tolerability; immediate-release products often need a noon dose, while extended-release products are typically once daily.
Typical adult total daily dosing varies by product. For extended-release (Concerta): 18–72 mg/day. Labeled maxima vary by product and delivery system; dose escalation that worsens sleep is typically avoided. A pretreatment evaluation including cardiac history, family history of sudden death, and assessment for tics/Tourette syndrome is recommended before initiation. If no improvement is observed within one month at appropriate doses, the medication should be discontinued.
Adolescents: doses should not exceed 2 mg/kg/day or 72 mg/day, whichever is less. Children under 6: not approved; younger children show higher drug exposures at equivalent mg/kg doses.
Concerta (extended-release) uses a nondeformable tablet that must be swallowed whole; it is not appropriate for patients with pre-existing severe gastrointestinal narrowing.
For insomnia or anxiety during titration, dose timing adjustments or a longer-acting delivery system are often tried before adding sedatives.
When switching between products, the first 1–2 weeks are often treated as a new trial, with attention coverage, appetite, sleep onset, and evening rebound tracked.
If benefit is inconsistent across the day, formulation duration is often matched to the problem: short acting for discrete work blocks, long acting for full-day coverage.

Monitoring & labs

Baseline and periodic blood pressure and heart rate (more often during titration).
Appetite and weight are tracked; meal and nutrition counseling is common if weight loss occurs.
Sleep onset, total sleep time, and evening rebound are monitored; timing/formulation changes are often tried first.
Anxiety, agitation, mood elevation, or hallucinations are monitored; stopping and reassessing is often considered if symptoms emerge.
Misuse/diversion risk is reviewed, and safe storage counseling is commonly documented.

Sources: DailyMed label(s); guideline statements; network meta-analysis context.

Adverse effects

FDA boxed warnings

Boxed warning: CNS stimulants carry a risk of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Risk is increased with higher dosage or unapproved methods of administration such as snorting or injection. Patients and families are educated about risks of abuse, proper storage, and disposal of unused medication. Misuse risk assessment and monitoring for diversion and escalating use are standard.

Common side effects (≥10%)

Appetite suppression / weight loss: Common early; weight/BMI tracking and meal timing or dose/formulation changes are often considered.
Insomnia: Often reflects late dosing or rebound; earlier dosing or formulation changes are often considered.
Increased heart rate / blood pressure: Vital sign monitoring is common; caution is typically used with cardiovascular disease or concomitant sympathomimetics.
Anxiety / irritability: Can emerge with rapid titration; dosing schedule adjustments and review of comorbid anxiety/bipolar risk are common.
Headache / GI upset: Often improves with time or food; slower titration is often considered.
Appetite rebound and evening “crash”: A longer delivery system or earlier dosing is often considered rather than adding sedatives.

Other notable effects

Psychiatric symptoms can include agitation, mood elevation, or hallucinations; stopping and reassessing is often considered if mania or psychosis emerges.
Peripheral vasculopathy (Raynaud-like symptoms) and rare priapism have been reported; education often includes when urgent care is warranted.
Tic worsening can occur; distinguishing medication-related tics from anxiety/akathisia-like restlessness is often important.
Growth suppression is documented: approximately 2 cm less height and 2.7 kg less weight over 3 years in children ages 7–13 compared with unmedicated peers. Periodic height/weight monitoring and shared decision-making about timing and duration of treatment are warranted. Not approved for children under 6.
Acute angle-closure glaucoma has been reported; patients with significant hyperopia or other risk factors for narrow angles should receive ophthalmologic evaluation before starting.
Increased intraocular pressure and open-angle glaucoma have been reported; benefit-risk assessment is warranted in patients with pre-existing elevated intraocular pressure.
Serotonin syndrome has been reported in postmarketing surveillance when methylphenidate is combined with serotonergic drugs (SSRIs, SNRIs, triptans); monitoring for symptoms is warranted during co-prescribing.
Other postmarketing reports include hepatocellular injury, rhabdomyolysis, stroke in pediatric patients, and pancytopenia.

Interactions

Contraindicated with MAO inhibitors (within 14 days) due to risk of hypertensive crisis.
Risperidone: coadministration may increase risk of extrapyramidal symptoms, particularly during dose changes of either drug. Relevant in psychiatric settings where stimulants and antipsychotics are co-prescribed.
Halogenated anesthetics: methylphenidate should be avoided on the day of planned surgery due to risk of sudden blood pressure and heart rate increase during anesthesia.
Antihypertensive drugs: methylphenidate may decrease the effectiveness of antihypertensive medications; blood pressure monitoring is warranted when co-prescribed.
Additive sympathomimetic effects with decongestants or other stimulants can worsen anxiety, tachycardia, or hypertension.
Alcohol can worsen impairment and may alter release characteristics of some extended-release formulations; co-use is generally avoided.

Other useful information

Symptom targets are often set in functional terms (missed tasks, late assignments, unsafe driving, interrupting) and reassessed after each titration step.
Sleep disorders (delayed sleep phase, obstructive sleep apnea) are often screened for, and sleep is often addressed first when attention complaints are sleep-driven.
When comorbid bipolar disorder or psychosis risk is present, primary illness stabilization is typically prioritized with closer monitoring for activation.
For diversion prevention, locked-storage counseling, limited sharing of refill information, and clear refill policies are common.
If response is partial, adherence, timing, and formulation fit are often reviewed before escalation; non-stimulants are often considered when misuse risk or activation limits stimulants.
A pregnancy exposure registry exists (1-866-961-2388). CNS stimulants can reduce placental perfusion through vasoconstriction. Methylphenidate is present in breast milk (estimated 0.16–0.7% of maternal weight-adjusted dose; milk/plasma ratio 1.1–2.7); breastfed infants should be monitored for agitation, insomnia, anorexia, and reduced weight gain.
Human abuse potential studies show extended-release formulations produce lower subjective euphoria than equivalent immediate-release doses, supporting formulation-based risk reduction strategies when abuse potential is a concern.

References

Related hubs:SMI toolkit·Support resources